JP2015522001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522001A5 JP2015522001A5 JP2015519379A JP2015519379A JP2015522001A5 JP 2015522001 A5 JP2015522001 A5 JP 2015522001A5 JP 2015519379 A JP2015519379 A JP 2015519379A JP 2015519379 A JP2015519379 A JP 2015519379A JP 2015522001 A5 JP2015522001 A5 JP 2015522001A5
- Authority
- JP
- Japan
- Prior art keywords
- poly
- repeating units
- biodegradable
- drug delivery
- ethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 49
- 239000004480 active ingredient Substances 0.000 claims description 25
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 8
- 108010036949 Cyclosporine Proteins 0.000 claims description 8
- 229960001265 ciclosporin Drugs 0.000 claims description 8
- 229930182912 cyclosporin Natural products 0.000 claims description 8
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 8
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 8
- 229960003387 progesterone Drugs 0.000 claims description 8
- 239000000186 progesterone Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 229920000747 poly(lactic acid) Polymers 0.000 claims 39
- 238000012377 drug delivery Methods 0.000 claims 29
- 230000002209 hydrophobic effect Effects 0.000 claims 20
- 229920000428 triblock copolymer Polymers 0.000 claims 17
- 229920001427 mPEG Polymers 0.000 claims 13
- 229920001223 polyethylene glycol Polymers 0.000 claims 13
- 239000004626 polylactic acid Substances 0.000 claims 13
- 229920000359 diblock copolymer Polymers 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 7
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims 7
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims 7
- 229960002418 ivermectin Drugs 0.000 claims 7
- 229960004400 levonorgestrel Drugs 0.000 claims 7
- 229920002959 polymer blend Polymers 0.000 claims 7
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 7
- 229960001534 risperidone Drugs 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000003960 organic solvent Substances 0.000 claims 6
- 229960003150 bupivacaine Drugs 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- -1 lactyl Chemical group 0.000 claims 4
- 229920001400 block copolymer Polymers 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000001704 evaporation Methods 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665192P | 2012-06-27 | 2012-06-27 | |
| US61/665,192 | 2012-06-27 | ||
| PCT/IB2013/001547 WO2014001904A1 (en) | 2012-06-27 | 2013-06-27 | Biodegradable drug delivery for hydrophobic compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522001A JP2015522001A (ja) | 2015-08-03 |
| JP2015522001A5 true JP2015522001A5 (enExample) | 2016-04-21 |
| JP6134788B2 JP6134788B2 (ja) | 2017-05-24 |
Family
ID=49117888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519379A Active JP6134788B2 (ja) | 2012-06-27 | 2013-06-27 | 疎水性組成物のための生分解性薬物送達 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20150150987A1 (enExample) |
| EP (1) | EP2866837B1 (enExample) |
| JP (1) | JP6134788B2 (enExample) |
| KR (1) | KR102189442B1 (enExample) |
| CN (1) | CN104582733B (enExample) |
| AU (1) | AU2013282891B2 (enExample) |
| BR (1) | BR112014031773B1 (enExample) |
| CA (1) | CA2877083C (enExample) |
| CL (1) | CL2014003531A1 (enExample) |
| CO (1) | CO7160098A2 (enExample) |
| CR (1) | CR20140581A (enExample) |
| CU (1) | CU24287B1 (enExample) |
| EA (1) | EA031522B1 (enExample) |
| ES (1) | ES2938586T3 (enExample) |
| IL (1) | IL236472B (enExample) |
| IN (1) | IN2014DN11063A (enExample) |
| MA (1) | MA37809B1 (enExample) |
| MX (1) | MX353280B (enExample) |
| SG (1) | SG11201408658PA (enExample) |
| TN (1) | TN2014000520A1 (enExample) |
| UA (1) | UA113549C2 (enExample) |
| WO (2) | WO2014001904A1 (enExample) |
| ZA (1) | ZA201409291B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2938019A1 (en) * | 2014-01-27 | 2015-07-30 | Centre National De La Recherche Scientifique | Retro-inverso analogs of spadin display increased antidepressant effects |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| CN107072948A (zh) * | 2014-09-30 | 2017-08-18 | 田纳西大学研究基金会 | 用于长效药物传递的原位凝胶剂 |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| FR3027522B1 (fr) | 2014-10-27 | 2016-12-09 | I Ceram | Composition poreuse chargee en principe actif |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| AU2016355236C1 (en) | 2015-11-16 | 2022-09-22 | Medincell | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11766400B2 (en) * | 2016-10-24 | 2023-09-26 | Yale University | Biodegradable contraceptive implants |
| EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
| LT3655038T (lt) * | 2017-07-17 | 2025-02-10 | Medincell S.A. | Farmacinė kompozicija |
| GB2568526A (en) | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
| CN108078911A (zh) * | 2017-12-08 | 2018-05-29 | 复旦大学 | 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法 |
| CN121554542A (zh) | 2018-08-22 | 2026-02-24 | 贝凯恩生物医疗技术有限公司 | 环孢菌素组合物及使用方法 |
| GB201900258D0 (en) * | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
| SI4027973T1 (sl) | 2019-09-13 | 2026-02-27 | Medincell S.A. | Formulacije za dostavo zdravil |
| CN111700876A (zh) * | 2020-03-12 | 2020-09-25 | 上海市肿瘤研究所 | 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法 |
| CN116847827A (zh) | 2020-12-16 | 2023-10-03 | 美蒂森股份公司 | 用于预防性治疗SARS-CoV-2病毒（COVID-19）的方法和组合物 |
| FI20215186A1 (en) | 2021-02-19 | 2022-08-20 | Rebio Tech Oy | Compositions for ophthalmic treatment |
| US20240148641A1 (en) | 2021-03-17 | 2024-05-09 | Medincell S.A. | Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers |
| US20240325294A1 (en) * | 2021-04-30 | 2024-10-03 | Medincell Sa | Etonogestrel formulation |
| WO2025081046A1 (en) * | 2023-10-11 | 2025-04-17 | The Brigham And Women's Hospital, Inc. | Ultra-high drug loading injectable drug suspension of hydrophobic drugs for long-term drug delivery |
| WO2026013080A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| DE60129838T2 (de) * | 2000-11-09 | 2008-04-30 | Astrazeneca Ab | Orale pharmazeutische zusammensetzung mit einem blockcopolymer |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| JP2004532847A (ja) | 2001-04-20 | 2004-10-28 | ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア | 疎水性薬物のためのミセル薬物送達システム |
| US6592899B2 (en) | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| PT1638535E (pt) * | 2003-06-26 | 2007-11-08 | Mediolanum Pharmaceuticals Ltd | Implantes subcutâneos com libertação inicial de princípio activo limitada e subsequente sua libertação extensiva com variação linear |
| US20050112170A1 (en) * | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
| CA2618404A1 (en) * | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
| CN101273963A (zh) * | 2007-11-22 | 2008-10-01 | 山东蓝金生物工程有限公司 | 一种含激素类抗癌药的温控缓释注射剂 |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| JP5449388B2 (ja) * | 2008-11-21 | 2014-03-19 | サミャン バイオファーマシューティカルズ コーポレイション | 耐性がん治療用高分子ミセル組成物及びその製造方法 |
| CN101810560B (zh) * | 2009-02-20 | 2013-07-10 | 北京大学 | 环孢a聚合物胶束组合物 |
| MY165655A (en) * | 2010-12-29 | 2018-04-18 | Medincell | Biodegradable drug delivery compositions |
-
2013
- 2013-06-27 KR KR1020157002309A patent/KR102189442B1/ko active Active
- 2013-06-27 JP JP2015519379A patent/JP6134788B2/ja active Active
- 2013-06-27 EA EA201492172A patent/EA031522B1/ru not_active IP Right Cessation
- 2013-06-27 BR BR112014031773-9A patent/BR112014031773B1/pt active IP Right Grant
- 2013-06-27 CN CN201380044335.7A patent/CN104582733B/zh active Active
- 2013-06-27 ES ES13758976T patent/ES2938586T3/es active Active
- 2013-06-27 IN IN11063DEN2014 patent/IN2014DN11063A/en unknown
- 2013-06-27 AU AU2013282891A patent/AU2013282891B2/en active Active
- 2013-06-27 MA MA37809A patent/MA37809B1/fr unknown
- 2013-06-27 WO PCT/IB2013/001547 patent/WO2014001904A1/en not_active Ceased
- 2013-06-27 MX MX2014015902A patent/MX353280B/es active IP Right Grant
- 2013-06-27 WO PCT/IB2013/001549 patent/WO2014001905A1/en not_active Ceased
- 2013-06-27 SG SG11201408658PA patent/SG11201408658PA/en unknown
- 2013-06-27 EP EP13758976.8A patent/EP2866837B1/en active Active
- 2013-06-27 CA CA2877083A patent/CA2877083C/en active Active
- 2013-06-27 CU CUP2014000148A patent/CU24287B1/xx unknown
- 2013-06-27 US US14/410,994 patent/US20150150987A1/en not_active Abandoned
- 2013-06-27 UA UAA201413827A patent/UA113549C2/uk unknown
-
2014
- 2014-12-15 TN TN2014000520A patent/TN2014000520A1/fr unknown
- 2014-12-16 CR CR20140581A patent/CR20140581A/es unknown
- 2014-12-17 ZA ZA2014/09291A patent/ZA201409291B/en unknown
- 2014-12-24 CL CL2014003531A patent/CL2014003531A1/es unknown
- 2014-12-25 IL IL236472A patent/IL236472B/en active IP Right Grant
- 2014-12-26 CO CO14284191A patent/CO7160098A2/es unknown
-
2018
- 2018-07-30 US US16/049,580 patent/US20190160171A1/en not_active Abandoned
-
2019
- 2019-11-22 US US16/692,487 patent/US20200085958A1/en not_active Abandoned
-
2020
- 2020-09-18 US US17/025,826 patent/US20210008216A1/en not_active Abandoned
-
2022
- 2022-05-19 US US17/748,464 patent/US20220354956A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103491946B (zh) | 可生物降解的药物释放组合物 | |
| JP6134788B2 (ja) | 疎水性組成物のための生分解性薬物送達 | |
| MX2020000618A (es) | Composicion farmaceutica. | |
| JP2018502956A5 (enExample) | ||
| WO2012131104A3 (en) | Biodegradable compositions suitable for controlled release | |
| JP2010515761A5 (enExample) | ||
| CY1123006T1 (el) | Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης | |
| DK1786400T3 (da) | Farmaceutiske sammensætning til tilförsel med kontrolleret frigivelse af biologisk aktive forbindelser | |
| RU2018105494A (ru) | Улучшенные системы доставки наночастиц | |
| JP2013533230A5 (enExample) | ||
| EA201401348A1 (ru) | Технология приготовления имплантируемой формы палиперидона | |
| JP2017533930A5 (enExample) | ||
| JP2016540060A5 (enExample) | ||
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| EP4659815A3 (en) | Formulation for administration of rna | |
| JP2009527505A5 (enExample) | ||
| RU2017111079A (ru) | Фармацевтическая композиция с улучшенной стабильностью | |
| JP2016531895A5 (enExample) | ||
| ES2914378T3 (es) | Capas adhesivas de polímeros solubles en agua | |
| JP2013530931A5 (enExample) | ||
| FI4027973T3 (fi) | Lääkkeensaattoformulaatioita | |
| JP2013542196A5 (enExample) | ||
| RU2011128540A (ru) | Композиции наночастиц | |
| RU2018107057A (ru) | Фрамацевтическая композиция с улучшенной устройчивостью при хранении и способ ее получения | |
| JP2016525129A5 (enExample) |